ABSTRACT Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology.
Mark W. Skinner +59 more
wiley +1 more source
New orphan disease therapies from the proteome of industrial plasma processing waste- a treatment for aceruloplasminemia. [PDF]
Zanardi A +31 more
europepmc +1 more source
Correction: Szebeni, J. Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease, and Platform-Inherent Challenges. <i>Pharmaceutics</i> 2025, <i>17</i>, 450. [PDF]
Szebeni J.
europepmc +1 more source
ABSTRACT Introduction Efficacy and safety of albutrepenonacog alfa (rIX‐FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real‐world data insights are required. Aim To describe real‐world effectiveness and tolerability of rIX‐FP in PwHB in Germany.
Johannes Oldenburg +9 more
wiley +1 more source
Orphan disease: Cherubism, optic atrophy, and short stature. [PDF]
Jeevanandham B +4 more
europepmc +1 more source
ABSTRACT Introduction There is limited qualitative published real‐world data on treatment patterns among people with severe haemophilia A (PwSHA), particularly those with unmet needs. Aim This qualitative study aimed to explore the impact of taking prophylactic extended half‐life factor VIII (EHL‐FVIII) or emicizumab on psychosocial and physical ...
Nana Kragh +7 more
wiley +1 more source
Anaesthesia and orphan disease: airway and anaesthetic management in Huntington's disease. [PDF]
Nguyen PT, Meeks D, Liotiri D.
europepmc +1 more source
Orcein is more sensitive than EVG for detecting intramural and extramural large vessel (venous) invasion than EVG and H&E in colorectal cancer. Background Large vessel invasion (VI) is a well‐established adverse prognostic factor in colorectal cancer (CRC).
Timothy Law +3 more
wiley +1 more source
Novel CHM mutations in Polish patients with choroideremia - an orphan disease with close perspective of treatment. [PDF]
Skorczyk-Werner A +3 more
europepmc +1 more source
Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe
An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 orphan diseases, only 50 orphan drugs (i.e. drugs developed to treat orphan diseases) were marketed in the EU by the end of 2008. In 2000, the EU implemented policies
Lut Mergaert +4 more
core

